Ergomed Past Earnings Performance
Past criteria checks 3/6
Ergomed has been growing earnings at an average annual rate of 59.9%, while the Life Sciences industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 23.3% per year. Ergomed's return on equity is 17.7%, and it has net margins of 10.3%.
Key information
59.9%
Earnings growth rate
60.1%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 23.3% |
| Return on equity | 17.7% |
| Net Margin | 10.3% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ergomed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 145 | 15 | 37 | 0 |
| 30 Sep 22 | 139 | 14 | 35 | 0 |
| 30 Jun 22 | 132 | 13 | 32 | 0 |
| 31 Mar 22 | 126 | 13 | 31 | 0 |
| 31 Dec 21 | 119 | 13 | 29 | 0 |
| 30 Sep 21 | 110 | 12 | 29 | 0 |
| 30 Jun 21 | 102 | 12 | 28 | 0 |
| 31 Mar 21 | 94 | 11 | 27 | 0 |
| 31 Dec 20 | 86 | 10 | 26 | 0 |
| 30 Sep 20 | 80 | 8 | 24 | 0 |
| 30 Jun 20 | 73 | 6 | 23 | 0 |
| 31 Mar 20 | 71 | 6 | 21 | 0 |
| 31 Dec 19 | 68 | 6 | 20 | 1 |
| 30 Sep 19 | 66 | 1 | 19 | 1 |
| 30 Jun 19 | 64 | -3 | 18 | 1 |
| 31 Mar 19 | 59 | -6 | 18 | 1 |
| 31 Dec 18 | 54 | -9 | 17 | 2 |
| 30 Sep 18 | 54 | -8 | 17 | 2 |
| 30 Jun 18 | 54 | -8 | 16 | 2 |
| 31 Mar 18 | 51 | -6 | 15 | 3 |
| 31 Dec 17 | 48 | -5 | 14 | 3 |
| 30 Sep 17 | 42 | -2 | 13 | 2 |
| 30 Jun 17 | 36 | 0 | 12 | 2 |
| 31 Mar 17 | 33 | 0 | 11 | 2 |
| 31 Dec 16 | 29 | 0 | 9 | 1 |
| 30 Sep 16 | 31 | 1 | 8 | 1 |
| 30 Jun 16 | 28 | 1 | 7 | 0 |
| 31 Mar 16 | 29 | 1 | 6 | 0 |
| 31 Dec 15 | 30 | 2 | 5 | 0 |
| 30 Sep 15 | 29 | 1 | 6 | 0 |
| 30 Jun 15 | 28 | 1 | 6 | 0 |
| 31 Mar 15 | 24 | 1 | 5 | 0 |
| 31 Dec 14 | 21 | 1 | 4 | 0 |
| 30 Sep 14 | 19 | 1 | 4 | 0 |
| 30 Jun 14 | 16 | 1 | 3 | 0 |
| 31 Mar 14 | 16 | 1 | 3 | 0 |
| 31 Dec 13 | 15 | 2 | 3 | 0 |
| 31 Dec 12 | 15 | 0 | 3 | 0 |
Quality Earnings: 2EM has high quality earnings.
Growing Profit Margin: 2EM's current net profit margins (10.3%) are lower than last year (10.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2EM has become profitable over the past 5 years, growing earnings by 59.9% per year.
Accelerating Growth: 2EM's earnings growth over the past year (18.2%) is below its 5-year average (59.9% per year).
Earnings vs Industry: 2EM earnings growth over the past year (18.2%) exceeded the Life Sciences industry 12.2%.
Return on Equity
High ROE: 2EM's Return on Equity (17.7%) is considered low.